Cargando…
The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome
Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/ https://www.ncbi.nlm.nih.gov/pubmed/36013401 http://dx.doi.org/10.3390/life12081222 |
_version_ | 1784774996768325632 |
---|---|
author | Sultana, Rizwana Sissoho, Fatoumatta Kaushik, Vinod P. Raji, Mukaila A. |
author_facet | Sultana, Rizwana Sissoho, Fatoumatta Kaushik, Vinod P. Raji, Mukaila A. |
author_sort | Sultana, Rizwana |
collection | PubMed |
description | Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, adverse drug–drug and drug–disease interactions, decreased quality of life, and increased healthcare cost in these patients. The current review of extant literature presents evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RA) as one pharmacologic intervention that provides a “one-stop shop” for OSA patients because of the multiple effects GLP-1RA has on comorbidities (e.g., hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic cardiovascular diseases) that commonly co-occur with OSA. Examples of glucagon-like peptide-1 receptor agonists approved by the FDA for diabetes (some of which are also approved for obesity) are liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide, and albiglutide. Prescribing of GLP-1RAs to address these multiple co-occurring conditions has enormous potential to reduce polypharmacy, cost, and adverse drug events, and to improve quality of life for patients living with OSA and diabetes. We thus strongly advocate for increased and early use of GLP-1RA in OSA patients with co-occurring diabetes and other cardiometabolic conditions common in OSA. |
format | Online Article Text |
id | pubmed-9410036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94100362022-08-26 The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome Sultana, Rizwana Sissoho, Fatoumatta Kaushik, Vinod P. Raji, Mukaila A. Life (Basel) Commentary Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, adverse drug–drug and drug–disease interactions, decreased quality of life, and increased healthcare cost in these patients. The current review of extant literature presents evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RA) as one pharmacologic intervention that provides a “one-stop shop” for OSA patients because of the multiple effects GLP-1RA has on comorbidities (e.g., hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic cardiovascular diseases) that commonly co-occur with OSA. Examples of glucagon-like peptide-1 receptor agonists approved by the FDA for diabetes (some of which are also approved for obesity) are liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide, and albiglutide. Prescribing of GLP-1RAs to address these multiple co-occurring conditions has enormous potential to reduce polypharmacy, cost, and adverse drug events, and to improve quality of life for patients living with OSA and diabetes. We thus strongly advocate for increased and early use of GLP-1RA in OSA patients with co-occurring diabetes and other cardiometabolic conditions common in OSA. MDPI 2022-08-12 /pmc/articles/PMC9410036/ /pubmed/36013401 http://dx.doi.org/10.3390/life12081222 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Sultana, Rizwana Sissoho, Fatoumatta Kaushik, Vinod P. Raji, Mukaila A. The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title | The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title_full | The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title_fullStr | The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title_full_unstemmed | The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title_short | The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome |
title_sort | case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410036/ https://www.ncbi.nlm.nih.gov/pubmed/36013401 http://dx.doi.org/10.3390/life12081222 |
work_keys_str_mv | AT sultanarizwana thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT sissohofatoumatta thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT kaushikvinodp thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT rajimukailaa thecaseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT sultanarizwana caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT sissohofatoumatta caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT kaushikvinodp caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome AT rajimukailaa caseforearlyuseofglucagonlikepeptide1receptoragonistsinobstructivesleepapneapatientswithcomorbiddiabetesandmetabolicsyndrome |